Tan XL, Lin Y, Rebbeck TR, et al. - In view of the preclinical studies suggesting that prostate cancer (PCa) metastases can be delayed using metformin and statins, researchers performed, this first human study investigating the individual and joint effects of statin and metformin use among patients with high-risk PCa. From the Surveillance, Epidemiology, and End Results-Medicare linked database, they identified 12,700 patients with high-risk PCa. Medicare Prescription Drug Event files were queried for exposure to metformin and statins. The analysis revealed lower all-cause and PCa mortality among high-risk patients in correlation with statin use alone or in combination with metformin. More pronounced effects were observed in postdiagnostic users: combination use of metformin/statins was linked with a 32% reduction in all-cause mortality, and 54% reduction in PCa mortality. they identified no significant correlation of metformin alone with either all-cause mortality or PCa mortality.